

Neonatal hyperthyroidism with craniolacunias



None of the authors declare a conflict of interest.

Gunma Children's Medical Center

Division of Endocrinology and Metabolism Junko Igaki

Division of Neonatology

Fumitaka Inoue Kenichi Maruyama

Division of Radiology

Shinitsu Hatakeyama

Background

Overt neonatal hyperthyroidism is estimated to occur in 1-2% of offspring of pregnant women with Graves' disease.

Preterm delivery, enhancement of bone including advanced bone age, craniosynostosis and microcephaly may be present. Liver dysfunction, hepatosplenomegaly, thymic enlargement, hyperviscosity, and thrombocytopenia present rarely. Ventriculomegaly was reported in three cases previously. Hydrocephalus due to aqueductal stenosis and Arnold-Chiari malformation type I have not reported previously. Craniosynostosis is a risk factor for hydrocephalus.

Craniolacunias is an abnormality of the calvarial bones of the skull, and is characterized by cavitation in the cranial vault as honey comb pattern. It is caused by non-ossification of the membranous skull due to intracranial decompression. It develops prenatally and is present at birth, while digital markings are caused by increased intracranial pressure and only appear after the first year of life. It is almost always associated with meningocele, and rarely with craniosynostosis, Arnold-Chiari malformation type II, and Klippel-Feil syndrome. However craniolacunias with neonatal hyperthyroidism has not previously been reported.

Purpose

This is the first report of two cases with craniolacunias and one case with hydrocephalus and Arnold-Chiari malformation type I associated with neonatal hyperthyroidism due to maternal Graves' disease, although neither of them had craniosynostosis.

Conclusion

Neonatal hyperthyroidism may be included in a differential diagnosis for craniolacunias.

Case 1 Male

[Mother] 27y/o: She developed Graves' disease at age 13 years and treated with ¹³¹I at age 26 years because of persistent symptoms. She received L-thyroxine after ¹³¹I. She was pregnant after last course of ¹³¹I, and added Thiamazole (MMI) at 25th wk. of pregnancy because of TRAb > 30 IU/L.

	gestational age	normal value	6 wk.	10 wk.	15 wk.	21wk.
TSH (μ IU/mL)	0.39-4.01	0.021	1.48	0.02	0.017	
FT3 (pg/mL)	2.13-4.07	3.06	2.31	3.53	3.22	
FT4 (ng/dL)	0.83-1.71	1.22	1.12	1.39	1.40	
TRAb (IU/L)	< 2.0	> 30	> 30	> 30	> 30	

History

He was delivered at 35w1d. BW 2342 g (0SD), Ht 45.0 cm (-0.1 SD), HC 31.0 cm (-0.3 SD). He was referred to our hospital because of tachypnea (RR 70/min).

3 hours old: BT 37.2°C, HR 149/min, BP 55/24 mmHg, RR 41/min.

He had exophthalmos, goiter, thymic enlargement, hepatosplenomegaly (Fig1)

laboratory findings

TSH < 0.005 μ IU/mL FT3 11.45 pg/mL FT4 6.16 ng/dL TRAb 75.3 %
AST 44 IU/L ALT 12 IU/L LDH 1085 IU/L γ -GT 395 IU/L CK 116 IU/L
NH3 67 μ g/dL WBC 19100 / μ L Hb 19.3 g/dL PLT 7.3万 / μ L

3 days old: BT 37°C, HR 120-150/min, BP 70/40 mmHg, RR40-60/min

irritability, jitteriness, restlessness, exophthalmos, periorbital edema

(Fig2). Sunset phenomenon. Anterior fontanel 3cm.

TSH < 0.005 μ IU/mL, FT3 29.79 pg/mL, FT4 > 7.77 ng/dL

KI 30mg/day (15mg/kg/day) and MMI 1 mg/day (0.5 mg/kg/day) were started

19 days old: dilated lateral ventricles (Fig3 MRI)

KI, MMI were tapered from 11 days old and discontinued at 46 days old.

L-thyroxine (LT4) 10 μ g/day (2.6 μ g/kg/day) was started at 37 days old because of central hypothyroidism.

Liver dysfunction was ameliorated at 9 days. Hepatosplenomegaly was still detected at 46 days old.

4 months old: Craniolacunias without craniosynostosis (Fig4).

Bone age (Roshe) 2 M/0

5 months old: sunset phenomenon, increased head circumference

(HC 45 cm (1.8 SD)). Hydrocephalus (Fig5 CT) due to aqueductal stenosis.

Third ventriculostomy was done.

TSH 0.03 μ IU/mL, FT3 3.36 pg/mL, FT4 1.34 ng/dL (with LT4 treatment)

16 months old: no symptoms of hydrocephalus (HC 48.8 cm (1.1SD)).

Arnold-Chiari malformation type 1 (MRI)

time course




Fig1



Fig2



Fig3




Fig4




Fig5




Fig6

Summary

Case 1: He developed neonatal hyperthyroidism, however his mother had been treated with antithyroid drug from the second trimester. Some clinical findings were infrequent, and included liver dysfunction, hepatosplenomegaly, thymic enlargement, hyperviscosity, thrombocytopenia, hydrocephalus due to aqueductal stenosis, Arnold-Chiari malformation type I, and craniolacunias, but craniosynostosis.

Case 2: She had craniolacunias without craniosynostosis, however neonatal hyperthyroidism ameliorated spontaneously.

Discussion

1. Various rare clinical findings associated with Graves' disease were observed in case 1. Although pathogenesis of those features remains to be elucidated, all those abnormalities were ameliorated by age 17 months but Arnold-Chiari malformation type I.

2. Hydrocephalus due to aqueductal stenosis and Arnold-Chiari malformation type I was found in case 1. Hydrocephalus due to aqueductal stenosis has not previously been reported in neonatal hyperthyroidism. Arnold-Chiari malformation type I with mild ventriculomegaly was reported in only one patient with mutation in thyrotropin receptor gene. It is not known whether the presence of the both disorders was consequence of fetal and neonatal hyperthyroidism or they are just coincidental representations.

3. Craniolacunias was presented in both of our two cases. Craniolacunias has never been reported in neonatal hyperthyroidism. Neither encephalocele nor craniosynostosis was observed in our cases. The cause of craniolacunias in our cases is not clear. Craniolacunias might be a consequence of fetal hyperthyroidism, considering the following. 1) Intracranial decompression during the fetal life is assumed to be the etiologic factor in the development of craniolacunias. 2) Hyperthyroid state during fetal life is suggested to have adverse effects on brain growth. 3) Head circumferences of our cases at birth were slightly small for the gestational age.

Further study including more patients with neonatal hyperthyroidism is needed to elucidate whether craniolacunias is associated with neonatal hyperthyroidism or not.

Case 2 Female

[Mother] 36 y/o: Leg edema and hypertension were recognized at 24th wk. of pregnancy. She was recognized as having exophthalmos and goiter, and diagnosed as having Graves' disease at 1 day post partum (TSH < 0.005 μ IU/mL, FT3 13.71 pg/mL, FT4 5.42 ng/dL, TRAb 23.5 %).

[History] Ventricular septal defect (VSD) was revealed at 27th wk. of gestation.

She was delivered at 33w5d. BW 1640 g (-1.1 SD), Ht 38.0 cm (-2.3 SD), HC 27.8 cm (-1.6 SD). (Apgar score 5-8). BT 37.5°C, HR 120 /min, BP 69/40 mmHg, RR 40/min. Anterior fontanel 1.5 cm. No signs of hyperthyroidism. Hb 18.8 g/dL, Plt 5.8万/mm³, AST 46 IU/L, ALT 9 IU/L

3 days old: HR 180 /min.

5 days old: poor weight gain, irritability, jitteriness, restlessness.

Diuretics were started for heart failure (cardiomegaly, increased pulmonary blood flow).

6 days old: Propranolol was started for tachycardia (HR 180-200/min) and discontinued at 40 days old.

Hyperthyroidism was ameliorated until 1 month old. L-T4 15 μ g/day (5 μ g/kg/day) was started for central hypothyroidism at 62 days old.

6 months old: Craniolacunias without craniosynostosis (Fig6)

Bone age (Roshe) 12 months HC 37.5 cm (-2.8 SD)

Radical operation for VSD was done.

8 months old: normal development. Euthyroid with L-T4 treatment.

time course

age in days	cord blood	5	12	19	27	40	48	54	61	68
propranolol										
L-T4										
furosemide, spironolactone										
TSH (μ IU/mL)	NR	0.007	0.01	0.01	0.01	0.015	0.077	0.127	0.413	0.067
NR 0.39-4.01										
FT3 (pg/mL)	NR	3.98	4.05	4.22	3.43	2.81	2.61	2.6	2.75	3.95
NR 2.13-4.07										
FT4 (ng/dL)	NR	3.52	2.57	2.16	1.56	0.97	0.86	0.71	0.7	1.7
NR 0.83-1.71										
TRAb (%)	NR	33.8								6.7
NR < 15										
AST (IU/L)		62	22							
ALT (IU/L)		17	13							
Hb (g/dL)		20.3	18.3	17.1	15.2					
PLT (x10 ⁴ /mm ³)		15.0	38.8	45.0	44.3					



Fig6

